Clinical: High-risk Cardiovascular
Apabetalone (RVX-208), our lead select BET inhibition small molecule, is the first epigenetic drug to be tested in humans for the reduction of major adverse cardiac events (MACE) in high-risk cardiovascular disease (CVD) patients with type 2 diabetes mellitus and chronic kidney disease (CKD). Apabetalone treatment is targeted for the 30 million high-risk CVD, diabetes and CKD patients who are at most risk for major adverse events such as heart attack, stroke and sudden death. Phase 3 clinical trial 'BETonMACE' has now commenced with a primary endpoint of time to first occurrence of MACE.
We are leaders in the field of epigenetics and BET inhibition, surpassing 8 years of clinical experience with apabetalone (RVX-208). This clinical knowledge has provided us with an advantage to develop additional epigenetic small molecules. Our focus and passion is to build effective collaborations with partners that deliver breakthrough medicines to improve people’s lives.
In April 2015 Resverlogix and Shenzhen Hepalink Pharmaceutical Co., Ltd., a leading global life science company, entered into one of the largest strategic partnerships for a single molecule for high-risk cardiovascular disease patients including those with diabetes and CKD. We completed a definitive agreement in July 2015 where Resverlogix is eligible to receive sales-based milestone payments from Hepalink, each ranging from US$5 million to US$90 million and Royalties based on net sales. This first partnership for apabetalone/RVX-208 provides Resverlogix with an important strategic partner that will provide ongoing accretive value to the asset through clinical and regulatory development in the Territories (China, Hong Kong, Macau and Taiwan) which will target high-risk patients to be included in Resverlogix's global Phase 3 BETonMACE trial.
Business Development Contact
Senior VP Business & Corporate Development
Phone: 403-254-9252 ext. 871